Share Price | Sight Sciences, Inc. Stock Analysis & Recommendation

Q: What does Sight Sciences, Inc. do?

Overview:Sight Sciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.Financial Snapshot:Most recent Net Sales: 18 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -14 Million (Quarterly Results - Mar 2025) Market-cap: USD 208.36 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.88 Return on Equity: -63.63% Price to Book: 2.68Contact Details:Registrar Address: Not available.

Q: Should I buy, sell or hold Sight Sciences, Inc.?

Based on the current situation with Sight Sciences, Inc., it would be advisable to hold your position rather than buy or sell. The company has shown flat results recently, with a return on capital employed (ROCE) at a concerning -52.87% and net sales for the quarter at their lowest point of USD 17.51 million. Additionally, the interest expenses have reached a high of USD 1.26 million, which adds to the financial strain.The stock is considered risky, especially since it has a negative EBITDA and is trading at valuations that are less favorable compared to its historical averages. While the stock has not generated any returns over the past year, it has seen a modest profit increase of 6.4%. On a more positive note, the company has a high level of institutional holdings at 65.14%, indicating that larger investors are backing it and likely have the resources to analyze its fundamentals more thoroughly than retail investors. Given these factors, holding your investment seems to be the most prudent approach at this time.

Q: Is Sight Sciences, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for Sight Sciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly MACD and KST indicators both signaling mild bearishness, along with Bollinger Bands indicating a bearish trend. The daily moving averages are mildly bullish, which provides some counterbalance but is outweighed by the overall bearish indicators. The stock has underperformed the S&P 500 significantly over the past year, with a return of -43.75% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

277.18 k

Shareholding (Sep 2025)

FII

15.81%

Held by 29 FIIs

DII

63.15%

Held by 14 DIIs

Promoter

9.94%

How big is Sight Sciences, Inc.?

22-Jun-2025

As of Jun 18, Sight Sciences, Inc. has a market capitalization of 208.36 million and reported net sales of 78.11 million with a net profit of -49.40 million over the latest four quarters. Shareholder's funds are at 87.52 million, and total assets are 142.84 million as of Dec 24.

View full answer

What does Sight Sciences, Inc. do?

22-Jun-2025

Sight Sciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $18 million and a net loss of $14 million as of March 2025. The company has a market cap of $208.36 million and does not pay dividends.

View full answer

Should I buy, sell or hold Sight Sciences, Inc.?

22-Jun-2025

Is Sight Sciences, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Sight Sciences, Inc. is in a mildly bearish trend, with weekly indicators signaling bearishness despite some daily moving averages being mildly bullish, and the stock has underperformed the S&P 500 by -43.75% compared to its 17.14% return over the past year.

View full answer

Compare Sight Sciences, Inc. with Similar Stocks

Semler Scientific, Inc.Harvard Bioscience, Inc.TELA Bio, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Flat results in Jun 25

ROCE(HY) Lowest at -57.1%

Risky - Negative EBITDA

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 337 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.80

Return on Equity

-71.72%

Price to Book

5.25

Revenue and Profits:

Net Sales:

20 Million

(Quarterly Results - Sep 2025)

Net Profit:

-8 Million

Total Returns

Total Returns (Price + Dividend)

Company does not have enough history

Risk Adjusted Returns v/s

News & Corporate Actions

News

Sight Sciences, Inc. Hits New 52-Week High at USD 5.86

Sight Sciences, Inc. has achieved a new 52-week high of USD 5.86, significantly up from its low of USD 2.03. With a market capitalization of USD 193 million, the company, despite losses and a negative return on equity, has outperformed the S&P 500 over the past year.

Read full news article

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

50.14%

EBIT Growth (5y)

-199.36%

EBIT to Interest (avg)

-12.78

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.88

Sales to Capital Employed (avg)

0.60

Tax Ratio

0.53%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

49.39%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.80

EV to EBIT

-2.99

EV to EBITDA

-3.02

EV to Capital Employed

16.51

EV to Sales

1.90

PEG Ratio

Dividend Yield

ROCE (Latest)

-552.17%

ROE (Latest)

-63.63%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 23 Schemes (11.1%)

Foreign Institutions

Held by 29 Foreign Institutions (15.81%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 1.53% vs 12.00% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 31.09% vs 16.20% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.90",
          "val2": "19.60",
          "chgp": "1.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.80",
          "val2": "-11.50",
          "chgp": "32.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.30",
          "val2": "1.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.20",
          "val2": "-11.90",
          "chgp": "31.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-397.10%",
          "val2": "-596.40%",
          "chgp": "19.93%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1.48% vs 13.74% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 7.21% vs 35.61% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "79.90",
          "val2": "81.10",
          "chgp": "-1.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-49.80",
          "val2": "-56.70",
          "chgp": "12.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.70",
          "val2": "5.40",
          "chgp": "-12.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-51.50",
          "val2": "-55.50",
          "chgp": "7.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-632.70%",
          "val2": "-706.60%",
          "chgp": "7.39%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

19.90

19.60

1.53%

Operating Profit (PBDIT) excl Other Income

-7.80

-11.50

32.17%

Interest

1.30

Exceptional Items

0.00

Consolidate Net Profit

-8.20

-11.90

31.09%

Operating Profit Margin (Excl OI)

-397.10%

-596.40%

19.93%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 1.53% vs 12.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 31.09% vs 16.20% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

79.90

81.10

-1.48%

Operating Profit (PBDIT) excl Other Income

-49.80

-56.70

12.17%

Interest

4.70

5.40

-12.96%

Exceptional Items

-2.00

0.00

Consolidate Net Profit

-51.50

-55.50

7.21%

Operating Profit Margin (Excl OI)

-632.70%

-706.60%

7.39%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -1.48% vs 13.74% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 7.21% vs 35.61% in Dec 2023

All Annual Results

Company CV

About Sight Sciences, Inc.

Sight Sciences, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Sight Sciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Sight Sciences, Inc.?

Watch in Real-Time

What does Sight Sciences, Inc. do?

Should I buy, sell or hold Sight Sciences, Inc.?

Is Sight Sciences, Inc. technically bullish or bearish?

Compare Sight Sciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Flat results in Jun 25

Risky - Negative EBITDA

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Sight Sciences, Inc. Hits New 52-Week High at USD 5.86

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Sight Sciences, Inc.

Company Coordinates